Evolva shareholders approve all Board proposals in AGM
Reinach, Switzerland, 10 June 2010 – Evolva Holding SA (SIX: EVE) The Annual General Meeting of Evolva Holding SA has approved the proposals that were put forward by the Board of Directors.
A total of 64 shareholders were present at the meeting that took place in Basel today. 100,219,641 shares were represented, or 71.8% of the total number of shares issued (139,526,594). A detailed overview of the agenda items and the proposals is available on the Evolva website.
-- ends --
Contact Details
| Neil Goldsmith, CEO | Jakob Dynnes Hansen, CFO | Paul Verbraeken, IR |
| neilg@evolva.com | jakobdh@evolva.com | paulv@evolva.com |
| + 41 61 485 2005 | + 41 61 485 2034 | + 41 61 485 2035 |
Download PDF
About Evolva Holding SA
Evolva's proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing synthetic chemistry and protein engineering approaches in the pharmaceutical industry today. Based on this technology, Evolva has a number of discovery and pre-clinical partnerships which in 2009 generated revenues of CHF 18.9 million. Evolva also has an attractive pipeline of compounds – one drug candidate (for renal and cardiovascular diseases) entered Phase I at the beginning of 2009, and two others (an anti-fungal and an anti-viral) are in late preclinical stages. Evolva is listed in the main standard of the SIX Swiss Exchange with the ticker EVE. For more information see www.evolva.com.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.